Education
About Us
Working with TipRanks
Follow Us
GE Healthcare Technologies Inc (GEHC)
NASDAQ:GEHC
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.05Last Year’s EPS
1.01Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized meaningful commercial momentum (record backlog, mid-single-digit organic growth in key areas, strong pharma/radiopharma growth, substantial free cash flow and enterprise deals) and clear progress on product launches and operational improvements (Heartbeat). However, the company faces meaningful near-term headwinds from tariffs, ongoing investments weighing on margins, and a cautious outlook for China that management explicitly budgeted as a decline for 2026. On balance the company communicated positive execution and a credible path to margin recovery and midterm targets, while flagging tangible near-term risks.Company Guidance
Strong Q4 Top-Line and Backlog
Q4 revenue of $5.7B with 4.8% organic year-over-year growth; product revenue +7.9% and service revenue +5.5%. Orders grew 2% in the quarter and the company exited with a record backlog of $21.8B (up $2.0B year-over-year and $600M sequentially) and a book-to-bill of 1.06x (TTM 1.07x).
Full-Year Revenue and EPS Performance
FY2025 revenue of $20.6B with 3.5% organic growth, adjusted EPS $4.59 (GAAP reconciliation referenced). Excluding tariff impacts, adjusted EPS would have grown ~12% for the year (company reported adjusted EPS growth of 2.2% including tariffs).
Strong Cash Generation and Capital Allocation
Q4 free cash flow of $916M (up $105M year-over-year); FY2025 free cash flow $1.5B with 72% free-cash-flow conversion. Returned capital via $200M in share repurchases (avg price $71) and continued dividend program; invested >$1.7B in innovation in 2025.
Pharmaceutical / Radiopharmaceutical Momentum
Pharma diagnostics delivered Q4 organic sales growth of 12.7%, EBIT growth of 10% and sequential margin expansion of 20 bps. Radiopharmaceutical ramp progress: CMO partners operating at ~95% on-time delivery, 220 doses delivered in the week ended Jan 23; company maintains confidence in ~$500M in "Vorcado" revenue by year-end 2028 and a long-term ~$1B opportunity.
Broad New Product and Regulatory Progress
Multiple major NPIs commercial/cleared or on-track: Omni Total Body PET and NexGen spec commercially available in Europe; Photonovo Spectra photon-counting CT, new MR systems, VividPioneer ultrasound adoption, Starguide GX CE mark, Alia Moveo FDA & CE—all regulatory timelines reported on track for the RSNA-launched portfolio.
Large Enterprise Deals and Recurring Revenue Traction
More than $7B in enterprise deals since spin, including multiyear agreements (University of Rochester seven-year collaboration, Sutter Health, Nuffield Health 20-year). Service business grew mid-single digits in 2025 and full-year service revenue +5.6%, increasing recurring revenue contribution and service capture rates.
Operational Improvements via Heartbeat
Deployment of 'Heartbeat' business system yielded an average monthly 25% improvement in past-due backlog versus prior year, improved manufacturing flexibility and visibility, and concrete tariff-mitigation actions (line transfers and partner network repositioning).
Strategic M&A to Expand Digital and Recurring Revenue
Announced planned acquisition of IntelliRed (expected first full year revenue ~ $270M, low-double-digit revenue growth, adjusted EBITDA >30%) with expected close in H1; smaller tuck-in acquisitions (e.g., Neon Metaphysics, Eichometrics) to accelerate cloud/SaaS and recurring revenue.
GEHC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GEHC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $78.78 | $82.63 | +4.89% |
Oct 29, 2025 | $79.37 | $77.35 | -2.54% |
Jul 30, 2025 | $77.65 | $71.58 | -7.82% |
Apr 30, 2025 | $68.00 | $70.24 | +3.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GE Healthcare Technologies Inc (GEHC) report earnings?
GE Healthcare Technologies Inc (GEHC) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is GE Healthcare Technologies Inc (GEHC) earnings time?
GE Healthcare Technologies Inc (GEHC) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GEHC EPS forecast?
GEHC EPS forecast for the fiscal quarter 2026 (Q1) is 1.05.